Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research)
Introduction. Mantle cell lymphoma is a rare type of B-cell non-Hodgkin lymphoma. According to statistics the incidence of this disorder amounts to 2-3 per 100,000 people; this is about 6% of all non-Hodgkin lymphomas. It has been established that various molecular genetic characteristics of mantle...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Bashkir State Medical University
2020-01-01
|
| Series: | Креативная хирургия и онкология |
| Subjects: | |
| Online Access: | https://www.surgonco.ru/jour/article/view/432 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849696847316123648 |
|---|---|
| author | E. I. Kankumasheva Ch. Kh. Valiakhmetova |
| author_facet | E. I. Kankumasheva Ch. Kh. Valiakhmetova |
| author_sort | E. I. Kankumasheva |
| collection | DOAJ |
| description | Introduction. Mantle cell lymphoma is a rare type of B-cell non-Hodgkin lymphoma. According to statistics the incidence of this disorder amounts to 2-3 per 100,000 people; this is about 6% of all non-Hodgkin lymphomas. It has been established that various molecular genetic characteristics of mantle cell lymphoma patients may present opportunities for a patient-specific approach to the disease prognosis and treatment strategy.Materials and methods. The paper presents a retrospective analysis of 45 mantle cell lymphoma patients treated at the GAUZ RKOD of the Ministry of Healthcare from 2015 until now. The data used in the analysis included clinical examination, lab panels, PET CT, tumour and bone marrow biopsy specimen cytology, histology and immunohistochemistry. We analysed the epidemiological data, the patients’ clinical presentation characteristics, treatment approaches, immediate and long-term outcomes.Results and discussion. We have established that the pathological process most frequently involves bone marrow (44%) and spleen (41%). The MIPI scores distribution was as follows: high in 14 (30%), medium in 20 (45%), low in 11 (41%). Ki67 was recorded at under 30% in four cases, in others it amounted to over 30%. In 2015–2017 patients were treated with the R-CHOP protocol with the following support with rituximab. PFS averaged at 20 months, 8 (17%) of patients remain in lasting remission (since 2015). In 2017 the R-BAC (high dose cytarabine for SCT candidates) and R-B (for the elderly and comorbid patients) became protocols of first line. Since 2018 eight patients have undergone auto-SCT (at the first late recurrence) as a treatment consolidation stage. As of now 13 patients have been examined in federal centres for del17p and the TP53 mutation.Conclusion. We have demonstrated the need for and the option of treatment depending on the results of molecular genetic testing of mantle cell lymphomas. |
| format | Article |
| id | doaj-art-32f5e4c0a2de45908fd2e57014030f8a |
| institution | DOAJ |
| issn | 2076-3093 2307-0501 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Bashkir State Medical University |
| record_format | Article |
| series | Креативная хирургия и онкология |
| spelling | doaj-art-32f5e4c0a2de45908fd2e57014030f8a2025-08-20T03:19:20ZengBashkir State Medical UniversityКреативная хирургия и онкология2076-30932307-05012020-01-019426126510.24060/2076-3093-2019-9-4-261-265344Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research)E. I. Kankumasheva0Ch. Kh. Valiakhmetova1Republican Clinical Oncology CenterRepublican Clinical Oncology CenterIntroduction. Mantle cell lymphoma is a rare type of B-cell non-Hodgkin lymphoma. According to statistics the incidence of this disorder amounts to 2-3 per 100,000 people; this is about 6% of all non-Hodgkin lymphomas. It has been established that various molecular genetic characteristics of mantle cell lymphoma patients may present opportunities for a patient-specific approach to the disease prognosis and treatment strategy.Materials and methods. The paper presents a retrospective analysis of 45 mantle cell lymphoma patients treated at the GAUZ RKOD of the Ministry of Healthcare from 2015 until now. The data used in the analysis included clinical examination, lab panels, PET CT, tumour and bone marrow biopsy specimen cytology, histology and immunohistochemistry. We analysed the epidemiological data, the patients’ clinical presentation characteristics, treatment approaches, immediate and long-term outcomes.Results and discussion. We have established that the pathological process most frequently involves bone marrow (44%) and spleen (41%). The MIPI scores distribution was as follows: high in 14 (30%), medium in 20 (45%), low in 11 (41%). Ki67 was recorded at under 30% in four cases, in others it amounted to over 30%. In 2015–2017 patients were treated with the R-CHOP protocol with the following support with rituximab. PFS averaged at 20 months, 8 (17%) of patients remain in lasting remission (since 2015). In 2017 the R-BAC (high dose cytarabine for SCT candidates) and R-B (for the elderly and comorbid patients) became protocols of first line. Since 2018 eight patients have undergone auto-SCT (at the first late recurrence) as a treatment consolidation stage. As of now 13 patients have been examined in federal centres for del17p and the TP53 mutation.Conclusion. We have demonstrated the need for and the option of treatment depending on the results of molecular genetic testing of mantle cell lymphomas.https://www.surgonco.ru/jour/article/view/432mantle cell lymphomanon-hodgkin lymphomaimmunohistochemistrycyclin d1genetic translocationfluorescence in situ hybridizationcytarabinebortezomib |
| spellingShingle | E. I. Kankumasheva Ch. Kh. Valiakhmetova Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research) Креативная хирургия и онкология mantle cell lymphoma non-hodgkin lymphoma immunohistochemistry cyclin d1 genetic translocation fluorescence in situ hybridization cytarabine bortezomib |
| title | Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research) |
| title_full | Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research) |
| title_fullStr | Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research) |
| title_full_unstemmed | Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research) |
| title_short | Mantle Zone Cell Lymphomas. New Opportunities for Diagnosis and Treatment (Epidemiological Research) |
| title_sort | mantle zone cell lymphomas new opportunities for diagnosis and treatment epidemiological research |
| topic | mantle cell lymphoma non-hodgkin lymphoma immunohistochemistry cyclin d1 genetic translocation fluorescence in situ hybridization cytarabine bortezomib |
| url | https://www.surgonco.ru/jour/article/view/432 |
| work_keys_str_mv | AT eikankumasheva mantlezonecelllymphomasnewopportunitiesfordiagnosisandtreatmentepidemiologicalresearch AT chkhvaliakhmetova mantlezonecelllymphomasnewopportunitiesfordiagnosisandtreatmentepidemiologicalresearch |